drugset / Trial / NCT03861793
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Timeline
- Start
- 2019-02-26
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | 3 mg | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |